Study Description
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Interventions
dabrafenib
trametinib
Eligibility Criteria
Inclusion Criteria:
Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
In the opinion of the Investigator would benefit from continued treatment.
Exclusion Criteria:
Patient has been previously permanently discontinued from study treatment in the parent protocol.
Patient's indication is commercially available and reimbursed in the local country.
Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
Study Location
Novartis Investigative Site
Recruiting
Budapest,H 1122,Hungary
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08035,Spain
Novartis Investigative Site
Recruiting
Madrid,28040,Spain
Novartis Investigative Site
Recruiting
Madrid,28050,Spain
National Institute of Health
Recruiting
Bethesda,Michelle Capozzoli (9999) email: [email protected] -- Robert Kreitman,20892 - Maryland,United States
Honor Health Research Institute
Recruiting
Scottsdale,Angela Neuckranz (480-323-3990) email: [email protected] -- Michael Gordon,85258 - Arizona,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.